ANI PHARMACEUTICALS, INC (ANIP) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
ANI PHARMACEUTICALS, INC (ANIP) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$283.66 MCurrent assets$825.43 MLiabilities$896.90 MAssets$1.49 BNon-current liabilities$613.25 MEquity$597.21 MNon-current assets$668.68 MGross equity(calculated)$651.36 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSCash and cash equivalentsAccounts receivable, netInventoriesPrepaid expenses and other current assetsInvestment in equity securitiesRestricted cashIntangible assets, netProperty and equipment, netDeferred tax assets, netGoodwillOther non-current assetsAccounts payableAccrued royaltiesReturned goods reserveAccrued government rebatesAccrued compensation and related expensesCurrent debt, netAccrued expenses and otherIncome taxes payableConvertible notes, netDebt, netOther non-current liabilitiesContingent considerationAdditional paid-in capitalRetained earnings (Accumulated deficit)Common Stock, $0.0001 par value, 66,000,000 shares authorized; 23,853,338 shares issued and 22,961,423 shares outstanding at June 30, 2026; 23,112,577 shares issued and 22,491,281 shares outstanding at December 31, 2025Current assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Treasury stock, 891,915 shares of common stock, at cost, at June 30, 2026 and 621,296 shares of common stock, at cost, at December 31, 2025Accumulated other comprehensive (loss) income, net of taxAccounts payableAccounts payable$73.83 MAccrued royaltiesAccrued royalties$55.83 MReturned goods reserveReturned goods reserve$44.01 MCurrent liabilitiesCurrent liabilities$283.66 MCash and cash equivalentsCash and cash equivalents$360.21 MCurrent assetsCurrent assets$825.43 MAccrued government rebatesAccrued government rebates$41.39 MAccrued compensation and related expensesAccrued compensation and related expenses$27.15 MAccounts receivable, netAccounts receivable, net$274.47 MLiabilitiesLiabilities$896.90 MAssetsAssets$1.49 BCurrent debt, netCurrent debt, net$21.33 MInventoriesInventories$143.15 MAccrued expenses and otherAccrued expenses and other$16.58 MPrepaid expenses and other current assetsPrepaid expenses and other current assets$31.94 MIncome taxes payableIncome taxes payable$3.53 MInvestment in equity securitiesInvestment in equity securities$15.63 MNon-current liabilitiesNon-current liabilities$613.25 MConvertible notes, netConvertible notes, net$309.01 MRestricted cashRestricted cash$35.00 KDebt, netDebt, net$280.16 MEquityEquity$597.21 MNon-current assetsNon-current assets$668.68 MIntangible assets, netIntangible assets, net$449.86 MOther non-current liabilitiesOther non-current liabilities$15.54 MContingent considerationContingent consideration$8.55 MProperty and equipment, netProperty and equipment, net$73.22 MGross equity (calculated)Gross equity(calculated)$651.36 MDeferred tax assets, netDeferred tax assets, net$71.50 MGoodwillGoodwill$62.48 MAdditional paid-in capitalAdditional paid-in capital$620.25 MOther non-current assetsOther non-current assets$11.62 MRetained earnings (Accumulated deficit)Retained earnings (Accumulated deficit)$31.10 MCommon Stock, $0.0001 par value, 66,000,000 shares authorized; 23,853,338 shares issued and 22,961,423 shares outstanding at June 30, 2026; 23,112,577 shares issued and 22,491,281 shares outstanding at December 31, 2025Common stock$3.00 KTreasury stock, 891,915 shares of common stock, at cost, at June 30, 2026 and 621,296 shares of common stock, at cost, at December 31, 2025Treasury stock−$53.82 MAccumulated other comprehensive (loss) income, net of taxAccumulated other comprehensive (loss) income, net−$327.00 K
Chart details

ANI PHARMACEUTICALS, INC (ANIP) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
1,494,112,000 US dollars
Current assets
825,433,000 US dollars
Non-current assets
668,679,000 US dollars
Liabilities
896,900,000 US dollars
Current liabilities
283,655,000 US dollars
Non-current liabilities
613,245,000 US dollars
Equity
597,212,000 US dollars
Cash and cash equivalents
360,212,000 US dollars
Accounts receivable, net
274,469,000 US dollars
Inventories
143,149,000 US dollars
Prepaid expenses and other current assets
31,942,000 US dollars
Investment in equity securities
15,626,000 US dollars
Restricted cash
35,000 US dollars
Intangible assets, net
449,857,000 US dollars
Property and equipment, net
73,223,000 US dollars
Deferred tax assets, net
71,495,000 US dollars
Goodwill
62,480,000 US dollars
Other non-current assets
11,624,000 US dollars
Accounts payable
73,830,000 US dollars
Accrued royalties
55,830,000 US dollars
Returned goods reserve
44,013,000 US dollars
Accrued government rebates
41,392,000 US dollars
Accrued compensation and related expenses
27,154,000 US dollars
Current debt, net
21,329,000 US dollars
Accrued expenses and other
16,575,000 US dollars
Income taxes payable
3,532,000 US dollars
Convertible notes, net
309,009,000 US dollars
Debt, net
280,155,000 US dollars
Other non-current liabilities
15,535,000 US dollars
Contingent consideration
8,546,000 US dollars
Additional paid-in capital
620,249,000 US dollars
Retained earnings (Accumulated deficit)
31,104,000 US dollars
Common Stock, $0.0001 par value, 66,000,000 shares authorized; 23,853,338 shares issued and 22,961,423 shares outstanding at June 30, 2026; 23,112,577 shares issued and 22,491,281 shares outstanding at December 31, 2025
3,000 US dollars
Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
0 US dollars
Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
0 US dollars
Treasury stock, 891,915 shares of common stock, at cost, at June 30, 2026 and 621,296 shares of common stock, at cost, at December 31, 2025
negative 53,817,000 US dollars
Accumulated other comprehensive (loss) income, net of tax
negative 327,000 US dollars
Gross equity (calculated)
651,356,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
ANI PHARMACEUTICALS, INC (ANIP) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!